Cathie Wood’s Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings
Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed.
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,
Biogen Exercises Option To Participate Developing Genentech’s Bispecific Antibody, Mosunetuzumab
Biogen Inc (NASDAQ: BIIB) has
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.
CMS Proposes Coverage Of Biogen’s Alzheimer’s Drug, With Conditions Apply
The Centers for Medicare & Medicaid Services (CMS)
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were two new molecular entities.
Novartis Launches New Share Buyback Program Of Up To $15B
Novartis AG (NYSE: NVS) is launching a
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial
Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would
Roche’s Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen R-CHOP. Data were presented at the American Society of Hematology (ASH) Annual Meeting and Exposition.